Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older
Public ClinicalTrials.gov record NCT06695130. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older
Study identification
- NCT ID
- NCT06695130
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 980 participants
Conditions and interventions
Conditions
Interventions
- Placebo (0.9% NaCl) Other
- RIV (recombinant influenza vaccine) Biological
- RIV + rC19 (dose 1) Biological
- RIV + rC19 (dose 2) Biological
- RIV + rC19 (dose 3) Biological
- RIV + rC19 (dose 4) Biological
- rC19 (dose 1) Biological
Other · Biological
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 17, 2024
- Primary completion
- Apr 2, 2026
- Completion
- Apr 2, 2026
- Last update posted
- May 4, 2026
2024 – 2026
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Phoenix Medical Clinic- Site Number : 8400009 | Phoenix | Arizona | 85020 | — |
| Synexus Clinical Research US, Inc. - Cerritos- Site Number : 8400002 | Cerritos | California | 90704 | — |
| Synexus Clinical Research US - Vista- Site Number : 8400010 | Vista | California | 92083 | — |
| Optimal Research - Florida- Site Number : 8400006 | Melbourne | Florida | 32934 | — |
| Synexus Clinical Research US - Orlando- Site Number : 8400007 | Orlando | Florida | 32806 | — |
| Optimal Research - Illinois- Site Number : 8400008 | Peoria | Illinois | 61614 | — |
| Synexus Clinical Research US - Evansville- Site Number : 8400004 | Evansville | Indiana | 47714 | — |
| Walgreens Clinical Trials-Malden- Site Number : 8400012 | Malden | Massachusetts | 02148 | — |
| Synexus Clinical Research US - Minneapolis- Site Number : 8400011 | Richfield | Minnesota | 55423 | — |
| Synexus-Las Vegas- Site Number : 8400005 | Las Vegas | Nevada | 89113 | — |
| Synexus Clinical Research US - Cincinnati- Site Number : 8400003 | Cincinnati | Ohio | 45236 | — |
| Synexus Clinical Research US - Anderson- Site Number : 8400001 | Anderson | South Carolina | 29621 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06695130, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06695130 live on ClinicalTrials.gov.